1-(3-Chlorophenyl)cyclohexanemethanamine | 933695-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-Chlorophenyl)cyclohexanemethanamine
• 英文别名: [1-(3-chlorophenyl)cyclohexyl]methanamine
• CAS: 933695-25-1
• 化学式: C₁₃H₁₈ClN
• 分子量: 223.746
• InChiKey: LAKSUFNIWOKMDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-Chlorophenyl)cyclohexanemethanamine 在 N-甲基吗啉 、 4-二甲氨基吡啶 、 硼烷四氢呋喃络合物 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 作用下， 以 二氯甲烷 为溶剂， 生成 1-(1-(3-chlorophenyl)cyclohexyl)-N-methylmethanamine
  参考文献：
  名称：

  Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

  摘要：

  The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.016
• 作为产物：
  描述：

  间氯氰苄 在 硼烷四氢呋喃络合物 、 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 生成 1-(3-Chlorophenyl)cyclohexanemethanamine
  参考文献：
  名称：

  Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

  摘要：

  The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.016

文献信息

• Cycloalkylamines as monoamine reuptake inhibitors
  申请人：Shao Liming

  公开号：US20070203111A1

  公开（公告）日：2007-08-30

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己胺衍生物及其在中枢神经系统（CNS）疾病的治疗和/或预防中的应用，例如抑郁症、焦虑症、精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及包含本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺、5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法和调节一个或多个单胺转运体的方法。
• CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Shao Liming

  公开号：US20100190861A1

  公开（公告）日：2010-07-29

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己基胺衍生物及其在治疗和/或预防中枢神经系统（CNS）疾病方面的应用，例如抑郁症，焦虑症，精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及含有本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺，5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法，以及调节一个或多个单胺转运体的方法。
• US8877975B2
  申请人：——

  公开号：US8877975B2

  公开（公告）日：2014-11-04
• US9868718B2
  申请人：——

  公开号：US9868718B2

  公开（公告）日：2018-01-16
• [EN] CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS<br/>[FR] CYCLOALKYLAMINES INHIBITEURS DU RECAPTAGE DES MONOAMINES
  申请人：SEPRACOR INC

  公开号：WO2007081857A2

  公开（公告）日：2007-07-19

  [EN] The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
  [FR] L'invention concerne de nouveaux dérivés de cyclohéxylamine et leur utilisation dans le traitement et/ou la prévention des troubles du système nerveux central (SNC), tels que la dépression, l'anxiété, la schizophrénie et les troubles du sommeil, ainsi que des procédés de synthèse de ceux-ci. L'invention concerne également des compositions pharmaceutiques contenant les composés de l'invention, ainsi que des procédés d'inhibition du recaptage des monoamines endogènes, telles que la dopamine, la sérotonine et la norépinéphrine de la fente synaptique, et des procédés de modulation d'un ou de plusieurs transporteurs de monoamines.